PF-Atlas › Clinical Trials › NCT07516951
A Study to Find an Efficacious and Safe Dose of CHF10067 in Participants With Idiopathic Pulmonary Fibrosis
CHF10067 · Phase 2
Registry ID
NCT07516951
Phase
Phase 2
Status
Recruiting
Drug / intervention
CHF10067
Sponsor
Chiesi Farmaceutici S.p.A.
Start
2026-07-08
Enrollment
240
Locations
1
About this trial
The purpose of this study is to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis (IPF). It is a phase IIb, multicentre, randomised, double-blind, placebo-controlled, three-arm parallel-group study. A total of 240 participants with IPF (Idiomatic Pulmonary Fibrosis) will be randomised in approximately 150 investigational sites in North and Latin America, Europe, Asia, and Oceania.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT07516951 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.